Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Article in Clinical Cancer Research (September 2020)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Clinical Cancer Research (September 2020)
Article in Medical Oncology (September 2019)
Article in Journal of Controlled Release (July 2019)